Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.
Spruce Biosciences has raised $60.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Spruce Biosciences's investors include Sands Capital Ventures, Novo Holdings, Abingworth, Omega Funds, HealthCap.
Spruce Biosciences is headquartered in South San Francisco, United States.
Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.
Spruce Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Spruce Biosciences — Funding & Investors." VCBacked, April 20, 2026, https://www.vcbacked.co/company/spruce-biosciences. Accessed August 1, 2026.
VCBacked. (2026). Spruce Biosciences — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/spruce-biosciences
{{cite web |title=Spruce Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/spruce-biosciences |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated